144 related articles for article (PubMed ID: 23129464)
1. Case report: artificial elevation of prothrombin time by telavancin.
Amanatullah DF; Lopez MJ; Gosselin RC; Gupta MC
Clin Orthop Relat Res; 2013 Jan; 471(1):332-5. PubMed ID: 23129464
[TBL] [Abstract][Full Text] [Related]
2. Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers.
Ero MP; Harvey NR; Harbert JL; Janc JW; Chin KH; Barriere SL
J Thromb Thrombolysis; 2014; 38(2):235-40. PubMed ID: 24132401
[TBL] [Abstract][Full Text] [Related]
3. Effect of telavancin (Vibativ) on routine coagulation test results.
Gosselin R; Dager W; Roberts A; Freeman L; Gandy L; Gregg J; Dwyre D
Am J Clin Pathol; 2011 Dec; 136(6):848-54. PubMed ID: 22095369
[TBL] [Abstract][Full Text] [Related]
4. Effects of telavancin on coagulation test results.
Barriere SL; Goldberg MR; Janc JW; Higgins DL; Macy PA; Adcock DM
Int J Clin Pract; 2011 Jul; 65(7):784-9. PubMed ID: 21564449
[TBL] [Abstract][Full Text] [Related]
5. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
[TBL] [Abstract][Full Text] [Related]
6. Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
Laohavaleeson S; Kuti JL; Nicolau DP
Expert Opin Investig Drugs; 2007 Mar; 16(3):347-57. PubMed ID: 17302529
[TBL] [Abstract][Full Text] [Related]
7. Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014-2016.
Duncan LR; Smith CJ; Flamm RK; Mendes RE
J Glob Antimicrob Resist; 2020 Mar; 20():118-123. PubMed ID: 31325617
[TBL] [Abstract][Full Text] [Related]
8. Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients.
Roch M; Varela MC; Taglialegna A; Rose WE; Rosato AE
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914961
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin.
McMullen AR; Lainhart W; Wallace MA; Shupe A; Burnham CD
Eur J Clin Microbiol Infect Dis; 2019 Dec; 38(12):2323-2330. PubMed ID: 31446513
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
MacGowan AP; Noel AR; Tomaselli S; Elliott HC; Bowker KE
Antimicrob Agents Chemother; 2011 Feb; 55(2):867-73. PubMed ID: 21078943
[TBL] [Abstract][Full Text] [Related]
11. Telavancin: a new lipoglycopeptide with multiple mechanisms of action.
Kanafani ZA
Expert Rev Anti Infect Ther; 2006 Oct; 4(5):743-9. PubMed ID: 17140351
[TBL] [Abstract][Full Text] [Related]
12. The role of telavancin in the treatment of MRSA infections in hospital.
Bassetti M; Mikulska M; Righi E; Nicolini L; Viscoli C
Expert Opin Investig Drugs; 2009 Apr; 18(4):521-9. PubMed ID: 19335280
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation.
Kidd JM; Sakon CM; Oleksiuk LM; Cies JJ; Pettit RS; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685468
[TBL] [Abstract][Full Text] [Related]
14. Warfarin monitoring with viscoelastic haemostatic assays, thrombin generation, coagulation factors and correlations to Owren and Quick prothrombin time.
Nilsson CU; Strandberg K; Reinstrup P
Scand J Clin Lab Invest; 2018 Sep; 78(5):358-364. PubMed ID: 29792060
[TBL] [Abstract][Full Text] [Related]
15. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
16. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
Karlowsky JA; Nichol K; Zhanel GG
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S58-68. PubMed ID: 26316559
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of whole blood prothrombin time (PT) and international normalized ratio (INR) using a Laser Speckle Rheology sensor.
Tripathi MM; Egawa S; Wirth AG; Tshikudi DM; Van Cott EM; Nadkarni SK
Sci Rep; 2017 Aug; 7(1):9169. PubMed ID: 28835607
[TBL] [Abstract][Full Text] [Related]
18. Telavancin: a novel lipoglycopeptide antimicrobial agent.
Attwood RJ; LaPlante KL
Am J Health Syst Pharm; 2007 Nov; 64(22):2335-48. PubMed ID: 17989443
[TBL] [Abstract][Full Text] [Related]
19. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
Harder S; Graff J; Klinkhardt U; von Hentig N; Walenga JM; Watanabe H; Osakabe M; Breddin HK
Thromb Haemost; 2004 Jun; 91(6):1137-45. PubMed ID: 15175800
[TBL] [Abstract][Full Text] [Related]
20. Quality assurance program for whole blood prothrombin time-international normalized ratio point-of-care monitors used for patient self-testing to control oral anticoagulation.
Tripodi A; Bressi C; Carpenedo M; Chantarangkul V; Clerici M; Mannucci PM
Thromb Res; 2004; 113(1):35-40. PubMed ID: 15081563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
